Wealth Enhancement Advisory Services LLC Boosts Holdings in Axon Enterprise, Inc $AXON

Wealth Enhancement Advisory Services LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 93.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 23,365 shares of the biotechnology company’s stock after buying an additional 11,262 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Axon Enterprise were worth $13,270,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Newbridge Financial Services Group Inc. lifted its stake in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 14 shares during the period. Vicus Capital lifted its position in Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 14 shares during the period. Evergreen Capital Management LLC boosted its holdings in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares in the last quarter. Blue Trust Inc. grew its position in shares of Axon Enterprise by 2.5% in the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after buying an additional 16 shares during the period. Finally, NorthCrest Asset Manangement LLC increased its stake in shares of Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 16 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Trading Down 2.1%

Shares of NASDAQ AXON opened at $450.46 on Friday. The firm’s 50 day moving average price is $506.17 and its 200-day moving average price is $594.01. Axon Enterprise, Inc has a 52-week low of $396.41 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The company has a market cap of $36.22 billion, a PE ratio of 296.36, a P/E/G ratio of 9.82 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. During the same period in the previous year, the business earned $2.08 EPS. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, equities research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the sale, the insider directly owned 55,588 shares of the company’s stock, valued at $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeri Williams sold 157 shares of Axon Enterprise stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director owned 1,159 shares of the company’s stock, valued at $567,910. The trade was a 11.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 23,855 shares of company stock valued at $13,299,928. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AXON shares. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Piper Sandler cut their price target on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Barclays reduced their price objective on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 price objective on Axon Enterprise in a research note on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and an average price target of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.